Other Events ·
Oncolytics Biotech replaces Ernst & Young with Baker Tilly US LLP as auditor
ONCYOncolytics Biotech Inc
On July 6, 2026, Oncolytics Biotech Inc. disengaged Ernst & Young LLP as its independent registered public accounting firm and engaged Baker Tilly US, LLP for the 2026 fiscal year. The change was driven by corporate restructuring. The company reported no disagreements with Ernst & Young regarding accounting principles, practices, or auditing procedures, although previous reports included an explanatory paragraph regarding the company's ability to continue as a going concern. The company operates in the biotechnology industry and develops immunotherapies for the treatment of cancer.